Trial Profile
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs KW 2449 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Kyowa Kirin
- 28 Apr 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 28 Apr 2010 Actual patient number (14) added as reported by ClinicalTrials.gov.
- 02 Apr 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.